Show simple item record

From patent to patient: analysing access to innovative cancer drugs.

dc.contributor.authorSharpe, E
dc.contributor.authorHoey, R
dc.contributor.authorYap, C
dc.contributor.authorWorkman, P
dc.date.accessioned2020-02-19T09:34:13Z
dc.date.issued2020-09-01
dc.identifier.citationDrug discovery today, 2020, 25 (9), pp. 1561 - 1568
dc.identifier.issn1359-6446
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3511
dc.identifier.eissn1878-5832
dc.identifier.doi10.1016/j.drudis.2020.01.004
dc.description.abstractAnalysis of cancer drugs licensed through the European Medicines Agency (EMA) in 2000-2016 shows that the number of authorisations increased over that timeframe. The median number of licensed drugs each year rose from six for 2000-2008 to 13.5 for 2009-2016. Over 2000-2016, there were 64 drug authorisations for haematological, 15 for breast, and 12 for skin cancer, but none for oesophageal, brain, bladder, or uterine cancer. Only 6% of authorisations included a paediatric indication. The average time for a drug to progress from patent priority date to availability on the National Health Service (NHS) increased from 12.8 years for drugs first licensed in 2000-2008 to 14.0 years for those licensed in 2009-2016. There was evidence that the most innovative drugs were not being prioritised for EMA licensing and NICE approval.
dc.formatPrint-Electronic
dc.format.extent1561 - 1568
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCI LTD
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleFrom patent to patient: analysing access to innovative cancer drugs.
dc.typeJournal Article
dcterms.dateAccepted2020-01-15
rioxxterms.versionofrecord10.1016/j.drudis.2020.01.004
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2020-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfDrug discovery today
pubs.issue9
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.publication-statusPublished
pubs.volume25
pubs.embargo.termsNo embargo
icr.researchteamClinical Trials & Statistics Unit
dc.contributor.icrauthorYap, Christina
dc.contributor.icrauthorWorkman, Paul


Files in this item

Thumbnail
Name:
DRUDIS_2613_202002001769698603 ...
Size:
362.5Kb
Format:
PDF
Description:
Accepted version
View/Open

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0